SCHEMBL6433871

SCHEMBL6433871

CC(C)(C)OC(=O)CNc1ccccc1C(=O)c1ccc2c(Cl)cnc(NC(=N)N)c2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 2/20 0.38
CCNT1 O60563 1/20 0.36
MEN1 O00255 1/20 0.35
AGTR1 P30556 1/20 0.35
KMT2A Q03164 1/20 0.35
PTGES O14684 1/20 0.35
DGAT2 Q96PD7 1/20 0.33
PLG P00747 1/20 0.33
PLAU P00749 1/20 0.33
MET P08581 2/20 0.33
F10 P00742 2/20 0.33
ALK Q9UM73 2/20 0.33
F2 P00734 1/20 0.33
F7 P08709 1/20 0.33
F3 P13726 1/20 0.33
CTNNB1 P35222 1/20 0.33
TCF7L2 Q9NQB0 1/20 0.33
MAPK10 P53779 2/20 0.33
PTPRC P08575 2/20 0.32
MAPK9 P45984 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6433651 0.87 CCNT1 (0.38) MAPK8CCNT1MEN1AGTR1KMT2A
SCHEMBL7397677 0.86 PLK1 (0.35) MAPK8MEN1AGTR1KMT2AMAPK10
Trifluoroacetic Acid SCHEMBL6434344 0.84 KLK1 (0.38) MAPK8MEN1AGTR1KMT2APLG
SCHEMBL6437624 0.83 PTPRC (0.43) CCNT1DGAT2PTPRCSTK17BSTK17A
SCHEMBL6433874 0.77 F2 (0.37) KMT2ADGAT2PLGPLAUF10
SCHEMBL6433846 0.77 DGAT2 (0.47) DGAT2PLAUPTPRCSTK17BSTK17A
SCHEMBL6433233 0.76 ROCK2 (0.41)
SCHEMBL7390695 0.76 CYP1A2 (0.34) MAPK8MEN1KMT2AMAPK10MAPK9
SCHEMBL6432761 0.75 PLAU (0.51) PLGPLAUF2
SCHEMBL7371013 0.75 AGTR1 (0.32) CCNT1MEN1AGTR1KMT2APTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 MAPK8 3371/4885CCNT1 886/4885MEN1 4591/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 MAPK8 3371/4885CCNT1 886/4885MEN1 4591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.